Drugs / JNJ-30979754
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00796003 | Jul 2008 → Oct 2010 | myelodysplastic syndrome | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-30979754 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00796003 ↗ |
| Route | Intravenous | “JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.” NCT00796003 ↗ |